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ABSTRACT The first line of treatment of obstructive sleep apnoea syndrome (OSAS) in children consists
of adenotonsillectomy (T&A). The aim of the present study was to evaluate treatment outcomes of OSAS
among obese children recruited from the community.
A cross-sectional, prospective, multicentre study of Spanish obese children aged 3–14 years, with four
groups available for follow-up: group 1: non-OSAS with no treatment; group 2: dietary treatment; group 3:
surgical treatment; and group 4: continuous positive airway pressure treatment.
117 obese children (60 boys, 57 girls) with a mean age of 11.3±2.9 years completed the initial (T0) and
follow-up (T1) assessments. Their mean body mass index (BMI) at T1 was 27.6±4.7 kg·m−2, corresponding
to a BMI Z-score of 1.34±0.59. Mean respiratory disturbance index (RDI) at follow-up was 3.3
±3.9 events·h−1. Among group 1 children, 21.2% had an RDI ⩾3 events·h−1 at T1, the latter being present
in 50% of group 2, and 43.5% in group 3. In the binary logistic regression model, age emerged as a
significant risk factor for residual OSAS (odds ratio 1.49, 95% confidence interval 1.01–2.23; p<0.05) in
obese children surgically treated, and RDI at T0 as well as an increase in BMI emerged as significant risk
factors for persistent OSAS in obese children with dietary treatment (OR 1.82, 95% CI 1.09–3.02 (p<0.03)
and OR 8.71, 95% CI 1.24–61.17 (p=0.03)).
Age, RDI at diagnosis and obesity are risk factors for relatively unfavourable OSAS treatment outcomes
at follow-up.
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Introduction
Sleep disordered breathing (SDB) is a highly prevalent condition potentially leading to intermittent
hypoxaemia, hypercapnia and disrupted sleep. SDB and, more specifically, obstructive sleep apnoea
syndrome (OSAS), have been associated with a large array of neurocognitive, behaviuoral, cardiovascular
and metabolic adverse consequences that are particularly prominent in obese children [1–5].
Adenotonsillar hypertrophy emerges as the most important condition associated with OSAS, even among
obese children [6–12]. It is widely accepted that the first line of treatment for OSAS consists of surgical
removal of upper airway adenoids and tonsils (T&A). However, persistence of abnormal
polysomnographic findings after T&A is frequent, being reported in 20–60% of cases, and with obese
children constituting a particularly important risk group for residual OSAS [13–22]. However, despite the
high rates of obesity in children in both developed and developing countries [23, 24], the overall evidence
regarding T&A outcomes in obese children is scarce.
We conducted the present two-phase study with the aim to assess the contributions of obesity and
adenotonsillar hypertrophy to paediatric OSAS. A previous report specifically focussed on the prevalence
and risk factors of OSAS in obese children recruited from the community [12]. In the initial study, we
found that the prevalence of OSAS in obese children was high, ranging from 21.5 to 39.5% depending on
the cut-off and the polysomnographically obtained respiratory disturbance used [12]. In the present study,
we examined the treatment outcomes of OSAS among obese children recruited from the community [12].
Subjects and methods
A detailed description of the methods pertaining to this cross-sectional, prospective multicentre study has
been published previously [12]. Briefly, inclusion criteria were ages between 3 and 14 years, body mass index
(BMI) >95th percentile for age and sex, and informed consent from parents or legal caretakers with assent
being obtained from children older than 12 years. The study was approved by the local human subject
committees of the institutions of the various participating cities in which paediatric sleep laboratories were
available. To guarantee the confidentiality of the data, coding of all data was performed, such that personal
information was not available to the investigator-based network. Exclusion criteria were failure to fulfil
inclusion criteria, and presence of known genetic syndromes or any chronic debilitating disease.
In Spain, the National Health System includes a programme of “well-child visits” from birth to 14 years of
age, in which systematic assessments of physical and mental development are conducted at pre-determined
ages, and include among many other items, including measurement of height and weight. Based on this
initial well-child assessment, obesity in the cohort was defined as the presence of a BMI corresponding to
>95th percentile for age and sex using national reference values [25, 26].
Decisions on the need for treatment during the first phase of the study were reached by strictly following
the Spanish consensus criteria, using a respiratory disturbance index (RDI) ⩾3 events·h−1 total sleep time
(TST) as the cut-off criterion for treatment of OSAS [14]. Based on the severity of OSAS, four groups were
accordingly available for follow-up.
Group 1: no polysomnographic evidence of OSAS (i.e. children with RDI <3 events·h−1 TST). No
treatment was administered. A random sample of 52 children who had an RDI <3 events·h−1 TST was
selected for the present follow-up study.
Group 2: mild OSAS. Children with RDI ⩾3 events·h−1 TST (but <10 events·h−1 TST) and/or presence of
obstructive hypoventilation without significant adenotonsillar hypertrophy (0–2 grade of tonsillar
hypertrophy and/or adenoid hypertrophy <25%). The treatment for this group consisted of supervised
dietary modification by a nutritionist.
Group 3: moderate–severe OSAS. Children with RDI ⩾3 events·h−1 TST, and apnoea–hypopnoea index
(AHI) ⩾10 events·h−1 TST, and/or presence of obstructive hypoventilation with significant adenotonsillar
hypertrophy (3–4 grade of tonsillar hypertrophy and/or adenoid hypertrophy >25%) as confirmed by
nasopharyngoscopy. The treatment approach was surgical T&A.
Group 4: moderate–severe OSAS. Children with RDI ⩾3 events·h−1 TST and AHI ⩾10 events·h−1 TST,
and/or presence of obstructive hypoventilation without nasopharyngoscopic adenotonsillar hypertrophy.
The treatment approach was continuous positive airway pressure (CPAP) treatment via a nasal mask.
65 of the 98 children who were diagnosed with OSAS using the criterion of an RDI ⩾3 events·h−1 TST in
the first phase of the study completed the specific treatment and follow-up protocol. However, 33 children
failed to appear for their scheduled follow-up clinical visits and assessments despite multiple telephone or
mailed reminders. No differences in age, sex and BMI z-score were present between the adherent and lost
to follow-up groups.
2 DOI: 10.1183/09031936.00013815
SLEEP | M.L. ALONSO-ÁLVAREZ ET AL.
All participants underwent assessment of their medical and sleep history, filled out a questionnaire about
snoring and an abbreviated version of the Pediatric Sleep Questionnaire (PSQ) [27], and were subjected to
a comprehensive physical examination that also included craniofacial evaluation by visual inspection, as
well as an otolaryngology assessment that included an awake nasopharyngoscopy under topical sedation,
followed by an overnight sleep study in the laboratory using standard techniques. Methodological details
have been published previously [12].
An overnight polysomnographic study was performed in the laboratory using standard techniques in the
presence of one of the caretakers throughout the study. Children arrived accompanied by one of their
parents to the sleep laboratory at approximately 19:30–20:00 h, and a lights-off routine was implemented
at 21:00 h with discontinuation of the sleep recordings at 08:00 h. After removal of movement and
technical artefacts, the studies were scored according to standard criteria as defined by the by the
American Academy of Sleep Medicine (AASM) [28]. The proportion of time spent in each sleep stage was
expressed as percentage of TST. Apnoea index and AHI were defined as the number of apneas, and the
number of apnoeas and hypopneas per hour of TST, respectively. The AHI, obstructive AHI (OAHI), and
the respiratory disturbance index (RDI) were also calculated. Furthermore, the flow limitation index was
calculated based on all events in which flow limitation was identified [28]. The sleep respiratory
disturbance index (SRDI) includes all types of index of respiratory events used in the analysis.
T&A was performed under general anaesthesia, and if severe OSAS was present, children were admitted to
the inpatient paediatric unit for postoperative cardiorespiratory monitoring. Adenoidectomy was performed
by curettage and haemostasis by compression or coagulation and tonsillectomy was performed by cold
dissection and haemostasis by ligation and bipolar coagulation. In those children who required CPAP
treatment, the pressure was adjusted by conventional titration as delineated by the AASM guidelines [29].
Data analysis
Data are presented as mean±SD. Descriptive statistics, Chi-squared analyses for trends, and odd ratios as
well as 95% confidence intervals were calculated. Comparisons of polysomnographic and demographic
characteristics before and after treatment were conducted with paired sample t-tests, or analysis of variance
followed by post hoc comparisons, with p-values adjusted for unequal variances when appropriate after
assessment using the Levene’s test for equality of variances, or Chi-squared analyses with the Fisher exact
test for dichotomous outcomes. Correlations were performed with the use of linear regression, followed by
calculation of Pearson correlation coefficients. To examine potential predictors for unsuccessful treatment
(i.e. RDI >3 events·h−1 TST after treatment), we performed a general lineal model and logistic regression
analysis. A two-tailed p<0.05 was considered as achieving statistical significance. All analyses were
conducted with the use of SPSS software (version 22.0; SPPS Inc., Chicago, IL, USA).
Results
A total of 117 obese children (60 boys, 57 girls) aged 10.3±2.9 and 11.3±2.9 years at baseline (T0) and
follow-up (T1), completed the initial and follow-up assessments within 11.8±4.1 months. Their mean BMI
at follow-up was 27.6±4.7 kg·m−2, corresponding to a BMI z-score of 1.34±0.59 (table 1).






Age years 10.35±2.89 11.32±2.85
Weight kg 59.90±21.01 65.25±21.72
Height m 1.46±0.18 1.51±0.17
BMI kg·m−2 27.06±4.05 27.63±4.7
BMI percentile 96.84±0.54 95.26±6.73
Neck circumference cm 33.82±3.72 33.82±3.42
Waist circumference/hip circumference ratio 0.90±0.07 0.88±0.07
Systolic blood pressure mmHg 103.2±14.3 105.9±12.4
Diastolic blood pressure mmHG 62.0±10.7 63.1±9.4
Data are presented as n (%) or mean±SD. BMI: body mass index; T0: baseline; T1: follow-up.
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Initial findings: T0
The mean abbreviated PSQ score was 4.56±3.82. Based on such a questionnaire, there was a 19.7%
prevalence of OSAS. Nasopharyngoscopic assessments showed that 60.7% of the children had no evidence of
choanal obstruction from enlarged adenoids, and that 31.6% had grade 0 tonsillar hypertrophy. Craniofacial
evaluations revealed that 2.6% of the children had retrognathia with 18.1% having dental malocclusion.
For the whole cohort, the mean RDI at T1 was 3.3±3.9 events·h−1 TST, with a mean obstructive RDI
(ORDI) of 3.0±3.7 events·h−1 TST and a mean obstructive AHI (OAHI) of 1.6±2.5 events·h−1 TST. Mean
nadir arterial oxygen saturation SaO2 was 90.7%±3.5%, and the total time spent with SaO2<90% (T90%)
was 0.2%±0.9% of TST; 52 children had no evidence of OSA (group 1), with 36 children being allocated to
group 2, 23 children in group 3 (T&A) and six children in group 4 (CPAP treatment) (table 2).
Follow-up findings: T1
Using an SRDI ⩾3 events·h−1 TST, the prevalence of OSAS was 17.1–34.2% depending on OAHI, ORDI
or RDI as the selected respiratory disturbance index. Based on a classification of OSAS as mild (SRDI ⩾3
and <5 events·h−1 TST), moderate (SRDI ⩾5 and <10 events·h−1 TST) or severe (SRDI >10 events·h−1
TST), severe OSAS was present in 3.4–8.5% of the children (table 3).
Using an RDI ⩾3 events·h−1 TST on polysomnography (PSG) at follow-up for the presence of OSAS:
Among subjects included in group 1 (non-OSAS, RDI <3 events·h−1 TST at T0), 41 (78.8%) of children
remained with an RDI <3 events·h−1 TST at T1 (non-OSAS) at follow-up, while 11 (21.2%) had an RDI
⩾3 events·h−1 TST at T1 (incident cases). Among group 2 (mild OSAS who received dietary treatment at
T0), 18 (50%) remained with an RDI ⩾ 3 events·h−1 TST at T1 (persistent cases) and 18 (50%) had an
RDI <3/h TST at T1 (remission cases). In Group 3 (moderate-severe OSAS who received surgical
treatment) 10 (43.5%) remained with an RDI ⩾3 events·h−1 TST at T1 (residual cases), while 13 (56.5%)
had RDI<3 events·h−1 TST at T1 (resolved cases). In group 4 (moderate–severe OSA who received CPAP
treatment) one (16.6%) remained with an RDI ⩾3 events·h−1 TST at T1 (residual cases), while five (83.3%)
had RDI <3 events·h−1 TST at T1 (controlled cases).
The residual OSAS were 30.4, 13.1 and 7.2% for OAHI ⩾1, OAH1⩾3 and OAHI ⩾5, respectively. Table 4
shows incidence, persistence and residual OSAS based on the different cut-off criteria used (RDI ⩾3,
OAHI ⩾3, OAHI ⩾1) on PSG for diagnosis of OSAS.
General linear model approaches were used to assess differences between study groups. Statistically
significant differences in the distribution of RDI and AHI between groups were observed (p<0.001), but
not in BMI and age (p=0.104 and p>0.05, respectively). After adjusting for age and BMI, age was
significantly associated with T0–T1 RDI changes (p<0.05) and AHI changes (p<0.05).
To examine potential predictors in development or persistence of OSAS at T1, a general linear model approach
was used. Comparing the incident group (n=11) and the non-OSA group that were originally included in group
1, there were no significant differences in age and BMI, but significant differences in the degree of tonsillar
hypertrophy emerged, with proportion of children with grade 3–4 tonsillar hypertrophy in the incident cases
being higher (27.3%) than among those who remained free of OSAS (2.4%, p<0.05; table 5). Comparisons of
group 2 subjects with persistent OSAS (n=18) to those without evidence of OSAS at T1 (remission cases), the
BMI in the remission cases decreased, while BMI increased in the group with persistent OSAS (change in BMI
from T0 to T1: −0.33±2.83 and 0.36±2.05 kg·m−2, respectively). The degree of tonsillar hypertrophy was not
statistically significant between those with remission compared to those with persistent OSAS (p>0.05; table 5).
In group 3, the residual group (n=10) and the resolved cases (n=13), revealed no significant differences in either
age or BMI. However, the risk of residual OSAS increased with increasing age and BMI (table 5).
A statistically significant association between BMI change from T0 to T1 (BMI1−BMI0) and parallel RDI
changes emerged (r=0.269; p=0.003) for the whole cohort, and was present in group 2 (r=0.362, p=0.03)
and group 3 (r=0.661; p<0.001).
In the binary logistic regression model, in group 1 (non-OSAS) and group 2 (mild OSAS with dietary
treatment), using OSAS a dichotomous outcome variables, sex, age, RDI at T0, BMI1−BMI0, retrognathia,
tonsillar hypertrophy and adenoid hypertrophy (>25%) as a co-variables, the odds ratio for tonsillar
hypertrophy was 4.37 (p=0.291) in group 1. In group 2, RDI at T0 and BMI1−BMI0 emerged as a
significant risk factors for OSAS persistent (OR 1.82, 95% CI 1.09–3.02 (p<0.03) and OR 8.71, 95% CI
1.24–61.17 (p=0.03)) respectively.
In the binary logistic regression model using OSAS as a dichotomous outcome variable, and sex, age, RDI
at T0, BMI1−BMI0 and retrognathia as co-variables, we found that age emerged as a significant risk factor
for residual OSAS (OR 1.49, 95% CI 1.01–2.23, p=0.047) in group 3, surgically treated. Although not
statistically significant, the OR for BMI change was 2.93 (p=0.523) and 8.57 (p=0.268) for retrognathia.
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TABLE 2 Polysomnographic measures at baseline (T0) and follow-up (T1) in 117 obese children in the four groups studied








Participants n 52 36 23 6
Respiratory measures
Respiratory events n
T0 9.56±5.32 51.44±32.37 131.13±130.60 173.0±115.15
T1 14.60±18.69¶ 28.14±27.89# 24.39±24.71# 16.50±34.07¶
Central apneas n
T0 0.62±1.10 3.29±10.04 6.0±10.72 1.17±1.47
T1 0.94±3.84 2.11±6.03 0.91±1.70¶ 4.17±5.49
Obstructive apnoeas n
T0 0.65±1.62 4.89±9.37 37.13±64.40 35.33±76.35
T1 2.04±5.45 3.47±5.85 1.00±2.31¶ 1.17±2.40
Mixed apneas n
T0 0.02±0.14 0.42±1.10 3.17±10.08 0.83±1.33
T1 0.62±3.64 0.64±1.58 0.09±0.42 0.0±0.0
Hypopnoeas n
T0 2.96±3.51 16.39±19.32 53.74±70.76 120.67±107.22
T1 5.00±8.61 9.44±14.07¶ 8.70±16.39¶ 10.83±25.56
Flow-limited events n
T0 5.60±4.70 26.53±19.56 30.17±37.99 14.83±15.54
T1 6.17±11.28 12.75±16.50¶ 13.00±15.68¶ 0.50±0.84¶
RDI events·h−1 TST
T0 1.48±0.83 8.57±8.35 18.92±20.15 30.10±18.33
T1 2.24±2.93 4.70±4.91# 3.60±3.50# 2.80±5.83¶
REMS RDI events·h−1 TST
T0 1.74±2.12 6.07±6.11 21.14±30.85 36.99±33.66
T1 1.57±2.80 3.69±4.31¶ 6.42±12.29¶ 1.92±1.27¶
NREMS RDI events·h−1 TST
T0 1.17±1.09 6.03±5.68 16.15±20.30 27.67±17.40
T1 2.02±3.14 4.14±5.10¶ 3.10±3.54¶ 1.53±3.26¶
ORDI events·h−1 TST
T0 1.34±0.85 7.98±4.91 17.88±19.06 29.29±18.28
T1 2.06±2.83 4.34±4.48# 3.33±3.60# 2.10±4.92¶
Central AHI events·h−1 TST
T0 0.09±0.18 0.59±2.03 0.85±1.55 0.19±0.17
T1 0.15±0.64 0.35±0.90 0.12±0.22¶ 0.69±0.94
OAHI events·h−1 TST
T0 0.57±0.60 3.57±3.90 13.54±19.77 27.36±18.89
T1 1.16±1.82¶ 2.25±2.99¶ 1.38±2.38# 2.05±4.77¶,+
Apnoea index events·h−1 TST
T0 0.20±0.32 1.40±2.82 6.74±12.64 6.34±13.25
T1 0.55±1.32 1.02±1.64 0.28±0.43¶ 0.88±1.34
Hypopnoea index events·h−1 TST
T0 0.47±0.57 2.70±3.01 7.62±10.16 21.19±18.54
T1 0.76±1.37 1.58±2.60 1.22±2.25¶ 1.86±4.36¶,+
Flow limited index events·h−1 TST
T0 0.86±0.72 4.36±3.26 4.08±4.85 2.62±2.29
T1 0.93±1.68 2.07±2.81¶ 1.89±2.11¶ 0.07±0.14¶,+
Baseline SaO2
T0 98.27±1.43 97.60±1.83 98.48±1.24 99.17±1.16
T1 97.96±1.01 97.54±1.36 98.35±0.94 99.17±0.41
Mean SaO2
T0 96.50±1.49 96.08±1.64 95.91±2.64 96.17±1.16
T1 96.31±1.18 96.17±1.36 96.57±1.30 97.00±1.09
Nadir SaO2
T0 91.29±3.63 90.44±3.02 86.86±10.96 87.50±3.61
T1 91.06±3.10 90.31±3.95 90.27±3.73¶ 93.00±1.55¶,+
T90%
T0 1.31±5.13 3.27±14.70 2.54±10.25 0.28±0.36
T1 0.23±1.28 0.28±0.68 0.09±0.34 0.00±0.00
Continued
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When we used a general lineal model for repeated measures, only in group 3 did surgically treated age
>11 years (p=0.033), retrognathia (p=0.026) and neck circumference (p=0.002) emerged as significant risk
factors for residual OSAS.
Discussion
This study prospectively assessed the outcomes of OSAS in a community-based cohort of children in
whom obesity was diagnosed by their primary care physicians. We previously described the high
prevalence of both snoring and OSAS in obese “healthy” children [12]. Here we found that, in obese
TABLE 2 Continued









T0 0.18±0.50 1.95±4.00 6.84±21.60 19.88±19.25
T1 0.24±0.56 1.57±2.67 0.94±2.38 0.42±0.57¶,+
Peak PETCO2 mmHg
T0 47.10±4.65 47.76±5.55 47.95±5.44 46.33±4.03
T1 47.15±5.11 44.26±5.45 47.84±5.38 50.00±3.69
PETCO2 >50 mmHg %TST
T0 2.79±6.62 4.30±11.34 10.01±22.11 1.82±4.45
T1 7.90±14.03¶ 3.06±7.82 3.80±9.11 3.32±7.98
Mean heart rate beats·min−1
T0 77.44±10.09 80.89±16.06 85.76±11.92 83.50±8.26
T1 75.10±10.45¶ 77.03±17.58¶ 76.05±12.37# 76.67±8.82¶,+
Sleep measures
Sleep efficiency %
T0 79.99±10.02 78.89±10.61 84.75±8.27 69.76±21.61
T1 81.54±9.89 79.74±16.55 83.11±11.36 81.86±13.69
NREMS latency mins
T0 34.80±24.07 31.83±23.27 24.13±19.58 46.42±26.29
T1 33.04±29.40 31.77±33.45 35.59±36.35 15.75±22.63
REMS latency mins
T0 123.72±54.33 123.31±79.70 127.98±75.81 222.30±74.64
T1 137.30±68.28 150.39±80.90 126.13±48.35 158.00±60.68
Awake %TST
T0 22.63±13.68 22.76±18.82 15.52±11.16 23.00±23.56
T1 24.48±16.38 19.60±20.56 18.10±15.17 14.70±10.06
N1 %
T0 11.82±8.00 11.29±10.70 12.02±7.80 14.25±5.90
T1 12.58±8.13 9.82±8.97 11.29±6.85 9.19±5.80
N2 %
T0 43.04±8.16 43.03±9.93 42.50±12.30 40.41±11.04
T1 42.67±8.75 41.79±12.77 43.32±11.61 46.31±8.23
N3 %
T0 25.95±10.85 29.21±12.17 27.70±23.85 36.02±16.13
T1 24.91±9.78¶ 31.20±13.69¶ 26.68±20.57 33.91±12.23
REMS %
T0 19.19±6.24 16.47±5.93 18.25±6.57 9.30±4.99
T1 19.85±5.14 17.18±6.11 20.71±7.33 12.97±3.87
Arousal index
T0 9.44±7.50 16.85±10.99 13.73±19.24 25.72±14.67
T1 10.30±7.63 12.64±6.74¶ 12.83±7.07 9.72±4.39¶,+
PLM index
T0 0.22±0.87 1.45±3.22 1.00±3.33 7.10±8.07
T1 0.15±0.64 1.31±3.82 1.24±4.46 1.00±1.41
Data are presented as mean±SD. OSA: obstructive sleep apnoea; RDI: respiratory disturbance index; TST: total sleep time; REMS: rapid eye
movement sleep; NREMS: non-REMS; ORDI: obstructive RDI; AHI: apnoea–hypopnea index; OAHI: obstructive AHI; SaO2: arterial oxygen
saturation; T90%: total time spent with SaO2 <90%; ODI: oxygen desaturation index; PETCO2: end tidal carbon dioxide tension; N1-N3: NREM
sleep stages; PLM: periodic leg movements during sleep. #: mean difference p<0.001; ¶: mean difference p<0.05; +: measures obtained while
subjected were receiving continuous positive airway pressure.
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TABLE 3 Prevalence and severity of OSAS based on different cut-off criteria in 117 obese children at baseline (T0) and follow-up (T1)
Diagnostic criterion Prevalence (95% CI) Severity-based prevalence
Mild OSAS (⩾3 and
<5 events·h−1 TST)




T0 T1 T0 T1 T0 T1 T0 T1
Participants n 248 117 117 117 117 117 117 117
OSAS (RDI ⩾3 events·h−1 TST) 39.5% (33.4–45.6%) 40 (34.2%) (25.2%–43.2%) 12 (10.3) 16 (13.7) 22 (18.8) 14 (12) 31 (26.5) 10 (8.5)
OSAS (ORDI ⩾3 events·h−1 TST) 35.9% (29.9–41.9%) 38 (32.5%) (23.6%–41.4%) 17 (14.5) 15 (12.8) 18 (15.4) 14 (12) 30 (25.6) 9 (7.7)
OSAS (OAHI ⩾3 events·h−1 TST) 21.5% (16.3–26.6%) 20 (17.1%) (9.8%–24.3%) 14 (12) 11 (9.4) 10 (8.5) 5 (4.3) 15 (12.8) 4 (3.4)
OSAS (OAHI >1 event·h−1 TST) 46.6% (40.6–53%) 44 (37.6%) (28.4%–46.8%)
Data are presented as n (%) (95% CI) or n (%), unless otherwise stated. OSAS: obstructive sleep apnoea syndrome; TST: total sleep time; RDI: respiratory disturbance index; ORDI:
obstructive respiratory disturbance index; OAHI: obstructive apnoea–hypopnoea index.
TABLE 4 Incidence, persistence and residual OSAS based on different cut-off criteria in 117 obese children
Groups for follow-up (T0-T1) n=117





OSAS treated with CPAP
Groups at T1
Diagnostic criteria Non-OSAS Incident cases Remission cases Persistent cases Resolved cases Residual cases Resolved cases Residual cases
RDI ⩾3 41 (78.84) 11 (21.15) 18 (50) 18 (50) 13 (56.5) 10 (43.5) 5 (83.3) 1 (16.6)
OAHI ⩾3 45 ( 86.5) 7 (13.5) 27 (75) 9 (25) 20 (86.9) 3 (13.1) 5 (83.3) 1 (16.6)
OAHI ⩾1 33 (70.2) 14 (29.8) 19 (46.3) 22 (53.6) 16 (69.6) 7 (30.4) 5 (83.3) 1 (16.6)
Data are presented as n (%). OSAS: obstructive sleep apnoea syndrome; RDI: respiratory disturbance index; OAHI: obstructive apnoea–hypopnoea index; TST: total sleep time. For RDI ⩾3
and OAHI ⩾3, number of subjects per group were non-OSAS: 52 (44.4%); mild OSAS treated by diet: 36 (30.8%); moderate-severe OSAS treated surgically: 23 (19.7%); and moderate-
severe OSAS treated with CPAP: 6 (5.1%). For OAHI ⩾1, number of subjects per group were non-OSAS: 47 (40.2%); mild OSAS treated by diet: 41 (35%); moderate-severe OSAS treated



















TABLE 5 Characteristics of the variables included in the general linear model
RDI AHI BMI BMI1−BMI0 Age at T1 years TH %
T0 T1 T0 T1 T0 T1
Non-OSAS
Non-OSAS n=41 1.40±0.79 0.92±0.75 0.52±0.52 0.39±0.42 25.79±3.24 26.16±3.99 0.37±2.38 10.93±2.73 2.4
Incident cases n=11 1.80±0.91 7.15±2.79 0.79±0.83 4.06±2.12 27.96±4.02 28.35±5.37 0.39±2.04 11.59±2.64 27.3
Mild OSAS
Remission cases n=18 5.97±2.19 1.71±0.89 2.62±1.63 0.60±0.64 27.84±4.04 27.50±5.02 −0.33±2.82 12.18±2.36 0
Persistent cases n=18 11.18±6.29 7.69±5.47 4.53±5.17 3.91±3.50 27.94±3.02 28.30±4.00 0.36±2.05 12.20±2.24 11.1
Moderate–severe OSAS treated surgically
Resolved cases n=13 20.57±24.21 1.22±0.87 13.99±23.98 0.43±0.55 26.22±5.19 26.42±3.07 0.19±3.81 9.69±3.62 0
Residual cases n=10 16.76±14.23 6.70±3.18 12.95±13.70 2.63±3.24 25.92±3.87 27.75±4.96 1.83±1.45 10.91±3.67 0
Moderate–severe OSAS treated with CPAP
Resolved cases n=5 28.12±19.77 0.42±0.18 24.87±19.99 0.10±0.17 33.31±3.55 35.21±3.90 1.90±1.74 11.82±2.25 0
Residual cases n=1 40.00 14.70 39.83 11.79 40.12 39.37 −0.75 16.75 0
OSAS: obstructive sleep apnoea syndrome; CPAP: continuous positive airway pressure; RDI: respiratory disturbance index; AHI: apnoea–hypopnoea index; BMI: body mass index; TH:



















children with OSAS treated by adenotonsillectomy, there was a high percentage of residual OSAS, and that
in a group of obese children with OSAS without adenotonsillar hypertrophy treated with nutritional
interventions, there was a high percentage of persistent OSAS. Furthermore, obese children without OSAS
during the initial assessment showed a high risk of developing OSAS at follow-up. Finally, we also
identified a portion of obese children with OSAS who presented no evidence of adenotonsillar
hypertrophy and were therefore best managed with CPAP.
Some methodological issues deserve comment. First, the prospectively designed recruitment of this cohort
was based on the initial diagnosis of obesity during routine well-child visits, thereby preventing any
potential a priori selection bias. Therefore, none of these children had been previously evaluated for
snoring or were clinically suspected or treated for OSAS. As in the previous study [12], we used previously
established consensus guidelines in Spain using a RDI ⩾3 events·h−1 TST as the cut-off criterion for
treatment of OSAS [14], and such an approach resulted in an OSAS prevalence of 34.2%. However, even if
we apply alternative criteria (e.g. ORDI ⩾3 events·h−1 TST, OAHI ⩾3 events·h−1 TST, or AHI
> 1 events·h−1 TST), the prevalence would still be very high (i.e. 17.1% to 37.6% for AHI >1 event·h−1
TST) [13, 14]. As shown in table 3, we also examined the distribution of OSAS and the effects of
treatment according to other widely accepted severity cut-off values.
The treatment of choice for OSAS in children is adenotonsillectomy; however, many studies show that in
obese children the success rate of surgery (expressed as a post-operative OAHI <1 event·h−1 TST or
<5 events·h−1 TST) is lower [30–36]. In a meta-analysis, 49% of obese children had a postoperative
AHI<5 events·h−1 TST, 25% of children had an AHI <2 events·h−1 TST and only 12% of children had a
postoperative AHI <1 event·h−1 TST [21]. In a retrospective multicentre study of 578 children that
included approximately 50% obese children, T&A resulted in a significant reduction of AHI, but complete
resolution of OSA was recorded in only 27.2%, using a post-T&A AHI cut-off of <1 event·h−1 TST [33]. In
this particular study, age (< or ⩾7 years) and BMI Z-score emerged as the two principal factors
contributing to post-T&A AHI outcomes [33]. An earlier prospective study carried out in 110 children
revealed that only 25% had normalisation of their postoperative PSG, and that pre-T&A AHI and obesity
were the major outcome determinants [30]. In another series, obese children had an OR of 3.7 (95% CI
1.3–10.8) for residual OSAS [35]. In the only randomised controlled trial to date, normalisation of
polysomnographic findings was observed in a large proportion of children in the early adenotonsillectomy
group when compared with the watchful waiting group (79 versus 46%), but occurred less frequently in
obese children [34]. Similarly unfavourable treatment outcomes of adenotonsillectomy (postoperative
OAHI <1 event·h−1 TST in 22.7–25% of cases) have been reported previously in a study of both lean and
obese children with OSAS [37].
In our study, 43.5% of children treated by T&A had residual OSAS defined as a postsurgical RDI
⩾3 events·h−1 TST, even if we apply alternative criteria (e.g. AHI ⩾3 events·h−1 TST, or AHI >1 event·h−1
TST or AHI >5 events·h−1 TST), the residual OSAS would still be high (i.e. 7.2–43.5%) (table 5). Our
study is therefore consistent with previous studies, showing that although T&A yields significant
improvements in respiratory abnormalities in children with OSAS, it is less likely to normalise PSG
findings in obese children. Interestingly, the severity of OSAS did not seem affect the response to T&A,
contrary to previous reports [36].
A potential opportunity for intervention that may improve overall T&A outcomes in obese children with
OSAS is the implementation of concurrent dietary modifications aiming at preventing the excessive
accelerated weight gain observed in this group [38–40]. There are few studies evaluating the effect of
weight loss as a treatment modality for OSAS in obese children. In a study of 61 obese children
undergoing an intensive supervised weight-loss programme, despite a higher median relative decrease in
BMI Z-score in OSAS compared with obese children without OSAS, 38% of the children with OSAS still
had significant OSAS despite losing weight [7]. However, this study also showed that weight loss is
effective in improving or resolving OSAS. In our study, group 2 consisting of children with mild OSAS
treated with diet, we observed improvements in respiratory parameters, with half of the children in this
group showing resolution of OSAS, albeit with the other half continuing to suffer from OSAS.
Comprehensive analysis of the potential factors associated with the presence, persistence or resolution of
OSAS in our cohort led to identification of two significant factors, namely tonsillar hypertrophy and BMI,
in addition to age. Notwithstanding, it is apparent that weight accrual in obese patients with OSAS is
clearly associated with incidence, persistence or residual OSAS, while weight reductions are associated with
improvement in polysomnographic parameters, as evidenced by the significant correlations between
changes in BMI and concomitant changes in RDI. In addition, children with residual OSAS show greater
weight gain with respect to children without residual OSAS after adenotonsillectomy; therefore, more
stringent dietary control in children with OSAS and obesity is necessary.
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Retrognathia and dental malocclusion were included in the analyses as potential factors associated with
residual OSAS. Retrognathia was a significant risk factor of residual OSAS in the general lineal model for
repeated measures (p=0.026). However, only 2.6% of the children included in this study had evidence of
retrognathia, which might explain why this risk factor did not achieve statistical significance. Nonetheless,
we believe that craniofacial factors need to be evaluated in the context of residual OSAS and, if present, be
followed by orthodontic therapy [13, 14].
As indicated above, a limitation of this study is the relatively small sample size in each of the subgroups
studied and their potential for inducing a beta 2 error. However, we should also remark that our total
follow-up sample consisted of 117 obese children, i.e. the largest obese cohort studied thus far in a
prospective fashion. We should also consider that the duration of follow-up was somewhat shorter than
ideal, whereby recurrence or de novo incidence of OSAS may occur over longer periods of time. Thus, it is
possible that the overall frequency of OSAS after treatment may be even greater at 2 or 5 years follow-up.
Another possible limitation is the lack of follow-up in 33 children. However as indicated above, no
differences in age, sex and BMI Z-score were present between the adherent and lost to follow-up groups.
Based on our present findings, we surmise that a greater influence of adenotonsillar hypertrophy appears
to be present in younger children in whom obesity operates as an OSAS risk enhancer, while the presence
of obesity takes over as the major determinant in older children.
In summary, in addition to the high prevalence of OSAS and the relatively unfavourable OSAS outcomes
involved in its treatment and follow-up, current findings place obesity in children as a major public health
problem, particularly when considering the potentially serious adverse consequences when obesity and
OSAS are concurrently present. These findings also indicate the need to develop effective tools that will
enable objective and accurate prediction of the response to treatment of obese children with OSAS
[41–45], and the identification of those at risk for developing OSAS with end-organ damage.
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